Ocular Therapeutix Inc (NASDAQ:OCUL)’s share price rose 7.3% during mid-day trading on Friday . The company traded as high as $2.75 and last traded at $2.64. Approximately 870,816 shares changed hands during trading, an increase of 60% from the average daily volume of 544,770 shares. The stock had previously closed at $2.46.

OCUL has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated a “buy” rating and set a $24.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, March 7th. Piper Jaffray Companies set a $14.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a research note on Friday, March 8th. ValuEngine downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, January 26th. Finally, Raymond James downgraded shares of Ocular Therapeutix from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $11.00 to $5.00 in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $9.18.

The company has a debt-to-equity ratio of 2.17, a quick ratio of 9.16 and a current ratio of 9.19. The company has a market cap of $111.81 million, a PE ratio of -1.68 and a beta of 1.80.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.45 million. Ocular Therapeutix had a negative net margin of 2,956.91% and a negative return on equity of 165.85%. As a group, equities analysts expect that Ocular Therapeutix Inc will post -1.42 EPS for the current fiscal year.

In other news, Director Jeffrey S. Heier bought 24,000 shares of the stock in a transaction on Friday, March 15th. The stock was bought at an average cost of $4.15 per share, for a total transaction of $99,600.00. Following the completion of the purchase, the director now directly owns 24,000 shares in the company, valued at $99,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard L. Md Lindstrom bought 56,441 shares of the stock in a transaction on Wednesday, March 13th. The stock was purchased at an average price of $4.33 per share, with a total value of $244,389.53. Following the completion of the purchase, the director now owns 100,000 shares of the company’s stock, valued at $433,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 90,441 shares of company stock valued at $385,490. 16.10% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA acquired a new stake in Ocular Therapeutix in the first quarter valued at approximately $30,000. JPMorgan Chase & Co. raised its holdings in shares of Ocular Therapeutix by 106.8% in the first quarter. JPMorgan Chase & Co. now owns 17,640 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 9,110 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in shares of Ocular Therapeutix by 100.0% in the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 20,000 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 10,000 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Ocular Therapeutix by 197.0% in the fourth quarter. Bank of America Corp DE now owns 26,271 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 17,425 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Ocular Therapeutix by 123.8% in the first quarter. The Manufacturers Life Insurance Company now owns 26,519 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 14,667 shares during the last quarter. Institutional investors own 47.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/ocular-therapeutix-ocul-stock-price-up-7-3/3021295.html.

Ocular Therapeutix Company Profile (NASDAQ:OCUL)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Further Reading: How can you know how many shares are floating?

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.